NRG Administrative Core Abstract The NRG Oncology (NRG) Administrative Core provides the leadership and infrastructure necessary to support the largest portfolio of clinical trials among the adult groups in the NCI National Clinical Trail Network (NCTN), a membership encompassing over 220 main member sites ? including nearly every Lead Academic Participating Site (LAPS) and a robust contribution to the overall management and success of the NCTN. NRG utilizes a highly successful multiple-PI model to provide remarkably capable leadership and scientific oversight, dynamic committee leadership and mentoring, knowledgeable and experienced administrative and operational leadership, and appropriate associated support. NRG, a group formed only four years ago, has leveraged the strengths of its legacy groups to form an integrated, modern clinical trials organization addressing specific populations within the NCTN. It is notable that NRG remained highly productive in all realms even while navigating the merger of the three legacy groups, a testament to the remarkable leadership of NRG and the thoughtful organizational structure put into place. In addition to supporting its own goals, NRG is a highly collaborative member of the NCTN. NRG co-led a number of trials with other groups, championed sixteen studies from other groups, participated in numerous NCI-appointed steering committees, workgroups, and task forces, and led the development of new remote monitoring standards. NRG has the leadership and infrastructure in place to continue to support the clinical trial and membership goals as well as continue to serve as engaged stakeholders in the overall management and success of the NCTN.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180868-07
Application #
9916742
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Nrg Oncology Foundation, Inc.
Department
Type
DUNS #
078695317
City
Philadelphia
State
PA
Country
United States
Zip Code
19103
Bertagnolli, Monica M; Blaney, Susan M; Blanke, Charles D et al. (2018) Current Activities of the Coalition of Cancer Cooperative Groups. J Natl Cancer Inst :
Michalski, Jeff M; Moughan, Jennifer; Purdy, James et al. (2018) Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 4:e180039
Dignam, James J; Hamstra, Daniel A; Lepor, Herbert et al. (2018) Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202. J Clin Oncol :JCO1800154
Blumenthal, Deborah T; Won, Minhee; Mehta, Minesh P et al. (2018) Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Neuro Oncol 20:966-974
Videtic, Gregory M; Paulus, Rebecca; Singh, Anurag K et al. (2018) Long term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase II study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys :
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Tew, William P; Sill, Michael W; Walker, Joan L et al. (2018) Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. Gynecol Oncol 151:257-263
Galanis, Evanthia; Anderson, S Keith; Miller, C Ryan et al. (2018) Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol 20:546-556
Richardson, Debra L; Sill, Michael W; Coleman, Robert L et al. (2018) Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol 4:196-202
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11

Showing the most recent 10 out of 357 publications